Geffner Michael

SEC source: 0001764013-25-000144 · wk-form4_1761338306.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,958

F1 · shares: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on October 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.03 - $19.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001764013-25-000140 · wk-form4_1760126587.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,553

F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on October 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.06 - $16.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001764013-25-000114 · wk-form4_1753477822.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,825

F1 · shares: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on July 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001764013-25-000109 · wk-form4_1752264894.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,210

F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 - $17.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001764013-25-000082 · wk-form4_1745612149.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,370

F1 · shares: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on April 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001764013-25-000068 · wk-form4_1744402047.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 227,719

F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 13,744 of these RSUs vested on April 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 - $13.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001764013-25-000053 · wk-form4_1743713398.xml · derivative · entry 2

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,063

Underlying: Common Stock · 143,063 shares

Expires 2035-04-01

F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

SEC source: 0001764013-25-000053 · wk-form4_1743713398.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 233,888

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

SEC source: 0001764013-25-000018 · wk-form4_1737753717.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,314

F1 · shares: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on January 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001764013-24-000179 · wk-form4_1729887814.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,971

F1 · shares: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on October 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001764013-24-000142 · wk-form4_1722025171.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,160

F1 · shares: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on July 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.37 - $28.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001764013-24-000089 · wk-form4_1714166555.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,616

F1 · shares: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on April 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001764013-24-000050 · wk-form4_1712262692.xml · derivative · entry 2

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,723

Underlying: Common Stock · 68,723 shares

Expires 2034-04-02

F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

SEC source: 0001764013-24-000050 · wk-form4_1712262692.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,877

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

SEC source: 0001764013-24-000017 · wk-form4_1706562671.xml · nonDerivative · entry 2

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,899

F1 · security: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 25,000 of these RSUs vested on January 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.45 - $38.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001764013-24-000017 · wk-form4_1706562671.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,052

F1 · security: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 25,000 of these RSUs vested on January 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.44 - $38.41 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.